Amphastar Pharmaceuticals (AMPH) FY2024 results: revenue $732 million, up 13.6% on the year
Amphastar Pharmaceuticals, Inc. (AMPH) reported revenue of $732 million for fiscal 2024, the year ended 31 December 2024, up 13.6% on the year before. Net income was $160 million, up 16.0%, and diluted earnings per share $3.06. The figures are the company's own, from the 10-K it filed with the SEC on 3 March 2025.
Revenue
$732 million
+13.6% on the year
FY2017FY2024
Operating margin
28.1%
30.6% a year earlier
FY2017FY2024
Net income
$160 million
+16.0% on the year
FY2017FY2024
Diluted EPS
$3.06
+17.7% on the year
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
213
184
89.2
+16.3%
Capital expenditure
41.0
38.2
24.0
+7.5%
Free cash flow
172
145
65.1
+18.6%
Free cash flow margin
23.5%
22.6%
13.1%
Cash from investing
-125
-649
-32.8
Cash from financing
-81.0
454
-26.4
Depreciation and amortisation
53.0
25.7
12.6
+105.8%
Share-based compensation
24.4
20.2
17.9
+20.4%
Buybacks
85.5
58.1
39.9
+47.0%
Diluted shares, weighted
52m
53m
52m
-1.8%
Shares outstanding at period end
48m
48m
48m
-0.9%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
732
639
529
+14.5%
Debt
614
603
76.6
+1.7%
Operating lease liabilities
41.9
29.7
23.7
+40.9%
Finance lease liabilities
0.4
0.6
0.8
-29.9%
Other liabilities
189
240
112
-21.1%
Total liabilities and equity
1,577
1,513
742
+4.3%
Fixed assets
297
283
238
+5.2%
Goodwill
3.0
3.2
3.1
-5.2%
Intangible assets
558
581
4.9
-3.9%
Investments
81.0
127
19.7
-36.3%
Cash and equivalents
152
144
156
+5.1%
Receivables
136
115
88.8
+18.6%
Inventory
154
106
104
+45.3%
Other assets
196
154
127
+27.4%
Total assets
1,577
1,513
742
+4.3%
10-K for the year ended 31 December 2024, filed 3 March 2025: the filing.